Novo Nordisk A/S
(NYSE : NVO)

( )
NVO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -1.39%34.030.9%$1163.63m
JNJJohnson & Johnson -0.12%142.810.7%$1084.56m
BMYBristol-Myers Squibb Co. 0.18%60.301.0%$985.23m
MRKMerck & Co., Inc. -1.11%78.700.7%$830.95m
ABBVAbbVie, Inc. 0.41%99.421.9%$788.32m
LLYEli Lilly & Co. -0.09%166.741.1%$696.31m
VXRTVaxart, Inc. 37.73%8.870.0%$300.02m
AZNAstraZeneca Plc -1.15%53.481.2%$295.19m
RPRXRoyalty Pharma Plc 2.04%47.050.1%$233.45m
NVSNovartis AG -0.75%87.800.2%$155.51m
RGENRepligen Corp. -1.94%124.147.1%$117.72m
GSKGlaxoSmithKline Plc -1.56%40.370.2%$117.39m
NVONovo Nordisk A/S -1.31%65.060.1%$94.47m
RETAReata Pharmaceuticals, Inc. -2.99%155.643.4%$81.74m
SNYSanofi -1.48%51.430.2%$73.80m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.